KIRhub 2.0· v2

Tofacitinib

90da6f6d-5e3b-54a1-9159-4521d67a8233 · FDA Approved · targets JAK3

Tofacitinib

MeasuredReference

Tofacitinib targets JAK3, JAK1, JAK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

JAK3 JAK1 JAK2 TYK2

Top hallmarks

tumor promoting inflammation2.1k
immune evasion1.1k
proliferation929

Top pathways disrupted

il6 jak stat3 signaling2.9k
interferon gamma response2.7k
allograft rejection2.5k

Resistance landscape — Tofacitinib

MeasuredReference

1 known oncogenic variants exist on Tofacitinib's top targets — see detail for inhibition impact.

JAK2 1 known variant
- JAK2 (V617F)

Open in new tab